Historical and Clinical Experiences of Gene Therapy for Solid Cancers in China
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Historical and Clinical Experiences of Gene Therapy for Solid Cancers in China
Authors
Keywords
-
Journal
Genes
Volume 8, Issue 3, Pages 85
Publisher
MDPI AG
Online
2017-02-25
DOI
10.3390/genes8030085
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent Advance in Tumor-associated Carbohydrate Antigens (TACAs)-based Antitumor Vaccines
- (2016) Danyang Feng et al. ACS Chemical Biology
- Induction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis
- (2016) Qi Zeng et al. BMC CANCER
- Oncolytic virus therapy: A new era of cancer treatment at dawn
- (2016) Hiroshi Fukuhara et al. CANCER SCIENCE
- RECIST 1.1—Update and clarification: From the RECIST committee
- (2016) Lawrence H. Schwartz et al. EUROPEAN JOURNAL OF CANCER
- Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
- (2016) Kaichao Feng et al. Science China-Life Sciences
- Treating Immunodeficiency through HSC Gene Therapy
- (2016) Claire Booth et al. TRENDS IN MOLECULAR MEDICINE
- CAR T Cell Therapy: A Game Changer in Cancer Treatment
- (2016) Hilde Almåsbak et al. Journal of Immunology Research
- Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1
- (2015) F. Touzot et al. BLOOD
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions
- (2015) Kazuko Sakai et al. Oncotarget
- Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial
- (2014) Yi Li et al. BMC Medicine
- Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumors
- (2014) Yi Li et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
- (2014) Saar Gill et al. IMMUNOLOGICAL REVIEWS
- Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: Analysis of therapeutic results in 112 cases
- (2014) Kenji Mitsudo et al. RADIOTHERAPY AND ONCOLOGY
- Randomized, controlled phase II study of post-surgery radiotherapy combined with recombinant adenoviral human p53 gene therapy in treatment of oral cancer
- (2013) S Liu et al. CANCER GENE THERAPY
- Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma
- (2013) S. L. Zhou et al. DISEASES OF THE ESOPHAGUS
- Advances in adenovirus-mediated p53 cancer gene therapy
- (2013) Hiroshi Tazawa et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- History of gene therapy
- (2013) Thomas Wirth et al. GENE
- Abscopal effect of radiation therapy: Interplay between radiation dose and p53 status
- (2013) Lidia Strigari et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- The Diarylheptanoid Hirsutenone Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin via Modulation of Apoptosis-inducing Factor and X-linked Inhibitor of Apoptosis
- (2013) Lee Farrand et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin
- (2012) Elisabet O. Berge et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- A killer promoting survival: p53 as a selective means to avoid side effects of chemotherapy
- (2012) Dominique Kranz et al. CELL CYCLE
- How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
- (2012) J. Prados et al. CURRENT MEDICINAL CHEMISTRY
- A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression
- (2012) Yasumoto Yamasaki et al. EUROPEAN JOURNAL OF CANCER
- Combination of Radiotherapy and Adenovirus-Mediated p53 Gene Therapy for MDM2-Overexpressing Hepatocellular Carcinoma
- (2012) Woong Sub KOOM et al. JOURNAL OF RADIATION RESEARCH
- Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union
- (2012) Seppo Ylä-Herttuala MOLECULAR THERAPY
- Clinical Therapeutic Effect and Biological Monitoring of p53 Gene in Advanced Hepatocellular Carcinoma
- (2011) Shixi Chen et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- Combining conditionally replicating adenovirus-mediated gene therapy with chemotherapy: A novel antitumor approach
- (2011) Guan Jiang et al. INTERNATIONAL JOURNAL OF CANCER
- p53gene therapy in combination with transcatheter arterial chemoembolization for HCC: One-year follow-up
- (2011) Yong-Song Guan WORLD JOURNAL OF GASTROENTEROLOGY
- Comparison of oncolytic adenoviruses for selective eradication of oral cancer and pre-cancerous lesions
- (2010) H J T van Zeeburg et al. GENE THERAPY
- Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial
- (2009) Geng Tian et al. ANTI-CANCER DRUGS
- Targeting p53 for enhanced radio- and chemo-sensitivity
- (2009) Chao Lu et al. APOPTOSIS
- A Phase 2 Trial of Surgery With Perioperative INGN 201 (Ad5CMV-p53) Gene Therapy Followed by Chemoradiotherapy for Advanced, Resectable Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, and Larynx
- (2009) George H. Yoo et al. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
- The significance ofTP53in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target
- (2009) K-John J. Cheung et al. BRITISH JOURNAL OF HAEMATOLOGY
- In vitro and Clinical Studies of Gene Therapy with Recombinant Human Adenovirus-p53 Injection for Oral Leukoplakia
- (2009) Y. Li et al. CLINICAL CANCER RESEARCH
- Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck
- (2009) J. Nemunaitis et al. CLINICAL CANCER RESEARCH
- Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma
- (2009) Zhi-xiang Yang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up
- (2009) Yong-song Guan et al. Journal of Zhejiang University-SCIENCE B
- Effect of Recombinant Adenovirus-p53 Combined With Radiotherapy on Long-Term Prognosis of Advanced Nasopharyngeal Carcinoma
- (2008) Jian-ji Pan et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers
- (2008) Xinghua Wang et al. MOLECULAR CANCER THERAPEUTICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started